Our central guiding principles in the setting of relapsed or refractory AML
| Guiding principles for relapsed or refractory AML . |
|---|
| 1. Enroll patients on clinical trials, when available |
| 2. Perform molecular testing to identify potential for targeted therapy and drug development |
| 3. Decipher mechanisms of treatment resistance |
| 4. Avoid reinduction attempts with multiple sequential courses of intensive cytotoxic chemotherapy |
| 5. Ensure appropriate patients proceed to allogeneic HCT, ideally when patients are MRD− |
| Guiding principles for relapsed or refractory AML . |
|---|
| 1. Enroll patients on clinical trials, when available |
| 2. Perform molecular testing to identify potential for targeted therapy and drug development |
| 3. Decipher mechanisms of treatment resistance |
| 4. Avoid reinduction attempts with multiple sequential courses of intensive cytotoxic chemotherapy |
| 5. Ensure appropriate patients proceed to allogeneic HCT, ideally when patients are MRD− |